HK1204914A1 - Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections - Google Patents

Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections Download PDF

Info

Publication number
HK1204914A1
HK1204914A1 HK15105031.3A HK15105031A HK1204914A1 HK 1204914 A1 HK1204914 A1 HK 1204914A1 HK 15105031 A HK15105031 A HK 15105031A HK 1204914 A1 HK1204914 A1 HK 1204914A1
Authority
HK
Hong Kong
Prior art keywords
cobicistat
tenofovir alafenamide
alafenamide hemifumarate
treatment
combination therapy
Prior art date
Application number
HK15105031.3A
Other languages
English (en)
Chinese (zh)
Inventor
Ramanathan Srinivasan
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of HK1204914A1 publication Critical patent/HK1204914A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15105031.3A 2012-02-03 2013-02-01 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections HK1204914A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261594894P 2012-02-03 2012-02-03
US61/594,894 2012-02-03
US201261618411P 2012-03-30 2012-03-30
US61/618,411 2012-03-30
US201261624676P 2012-04-16 2012-04-16
US61/624,676 2012-04-16
US201261692392P 2012-08-23 2012-08-23
US61/692,392 2012-08-23
US201261737493P 2012-12-14 2012-12-14
US61/737,493 2012-12-14
PCT/US2013/024438 WO2013116720A1 (en) 2012-02-03 2013-02-01 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

Publications (1)

Publication Number Publication Date
HK1204914A1 true HK1204914A1 (en) 2015-12-11

Family

ID=47722563

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15105031.3A HK1204914A1 (en) 2012-02-03 2013-02-01 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
HK15103394.9A HK1202801A1 (en) 2012-02-03 2013-02-01 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15103394.9A HK1202801A1 (en) 2012-02-03 2013-02-01 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

Country Status (15)

Country Link
US (2) US20150105350A1 (https=)
EP (1) EP2809323A1 (https=)
JP (1) JP6059255B2 (https=)
KR (1) KR20140119177A (https=)
CN (1) CN104105484A (https=)
AU (3) AU2013204731C1 (https=)
BR (1) BR112014018918A8 (https=)
CA (1) CA2863662A1 (https=)
EA (1) EA026138B1 (https=)
HK (2) HK1204914A1 (https=)
IL (1) IL233874A0 (https=)
MD (1) MD20140091A2 (https=)
MX (1) MX2014009172A (https=)
NZ (1) NZ629896A (https=)
WO (2) WO2013116730A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3150586T3 (pl) 2007-02-23 2020-06-01 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
HRP20161696T4 (hr) * 2011-08-16 2023-10-13 Gilead Sciences, Inc. Tenofovir alafenamid hemifumarat
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
HK1220390A1 (zh) * 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
IN2013CH05455A (https=) * 2013-11-27 2015-08-07 Laurus Labs Private Ltd
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
CA2942877A1 (en) * 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN105518011B (zh) * 2014-04-21 2018-07-27 四川海思科制药有限公司 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
PT3166607T (pt) * 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
CA2960436C (en) 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
CN105237571B (zh) * 2014-11-28 2018-03-09 成都苑东生物制药股份有限公司 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
JP2018502118A (ja) * 2015-01-03 2018-01-25 マイラン・ラボラトリーズ・リミテッドＭｙｌａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ 非晶質ヘミフマル酸テノホビルアラフェナミドおよびその予備混合物を調製するプロセス
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
CN104817593B (zh) * 2015-04-27 2016-11-16 广州同隽医药科技有限公司 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺
PT3316868T (pt) * 2015-06-30 2020-04-21 Gilead Sciences Inc Formulações farmacêuticas compreendendo tenofovir e emtricitabina
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
WO2017023694A1 (en) 2015-08-03 2017-02-09 Pop Test Oncology Llc Pharmaceutical compositions and methods
CN105153231A (zh) * 2015-08-28 2015-12-16 浙江车头制药股份有限公司 一种一苯基pmpa的制备方法
SG11201802983TA (en) * 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
CN109195633A (zh) * 2016-02-12 2019-01-11 西普拉有限公司 包含抗逆转录病毒药物和药代动力学增效剂的药物组合物
CN107179355B (zh) * 2016-03-11 2021-08-10 广东东阳光药业有限公司 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法
WO2018039157A1 (en) * 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN108070003A (zh) * 2016-12-02 2018-05-25 上海博志研新药物技术有限公司 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
US20190374557A1 (en) * 2017-02-28 2019-12-12 Alexandre Vasilievich Ivachtchenko Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof
CN106928277A (zh) * 2017-03-16 2017-07-07 江苏诚信药业有限公司 一种替诺福韦艾拉酚胺合成的工艺方法
EP3600332B1 (en) 2017-03-20 2023-12-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Hiv post-exposure prophylaxis
RU2019136678A (ru) * 2017-04-18 2021-05-18 Сипла Лимитед Комбинированная терапия для применения в лечении ретровирусных инфекций
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
US20190151307A1 (en) * 2017-10-24 2019-05-23 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
CN110305163A (zh) * 2018-03-27 2019-10-08 北京济美堂医药研究有限公司 替诺福韦艾拉酚胺半富马酸盐的制备方法
CN108484672A (zh) * 2018-05-23 2018-09-04 中国药科大学制药有限公司 磷丙替诺福韦的手性拆分方法
CN109081853A (zh) * 2018-09-03 2018-12-25 南京正大天晴制药有限公司 一种磷丙替诺福韦有关物质的制备方法
US20220257540A1 (en) * 2019-06-28 2022-08-18 Anhui Ronghang Biotech Development Co., Ltd. Compositions and methods for treatment of hepatitis b virus infection
EP3999067A1 (en) 2019-07-19 2022-05-25 The United States of America, as represented by the Secretary, Department of Health and Human Services Hiv pre-exposure prophylaxis
CN111606949A (zh) * 2020-03-13 2020-09-01 浙江车头制药股份有限公司 一种磷丙替诺福韦杂质的制备方法
CN111303209A (zh) * 2020-03-21 2020-06-19 石家庄龙泽制药股份有限公司 一种丙酚替诺福韦降解杂质的制备方法
WO2022118020A1 (en) * 2020-12-02 2022-06-09 Cipla Limited Method of treating viral infection
AU2024240009A1 (en) 2023-03-17 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
EP4640214A1 (en) * 2024-03-28 2025-10-29 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet comprising tenofovir alafenamide monofumarate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB453061A (en) 1935-03-23 1936-09-04 Charles Howard Twigg Improvements in and relating to gas heated geysers and water heaters
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
CZ304734B6 (cs) * 2000-07-21 2014-09-10 Gilead Sciences, Inc. Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
DE10153078A1 (de) 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
MXPA05007016A (es) 2003-01-14 2005-09-12 Gilead Sciences Inc Composiciones y metodos para terapia antiviral de combinacion.
PL3150586T3 (pl) * 2007-02-23 2020-06-01 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
DK2393485T3 (en) * 2009-02-06 2015-10-26 Gilead Sciences Inc Bilayer COVERING ELVITEGRAVIR, COBICISTAT, emtricitabine and tenofovir
HRP20161696T4 (hr) * 2011-08-16 2023-10-13 Gilead Sciences, Inc. Tenofovir alafenamid hemifumarat

Also Published As

Publication number Publication date
JP2015505565A (ja) 2015-02-23
IL233874A0 (en) 2014-09-30
AU2013204731A1 (en) 2013-08-22
EA026138B1 (ru) 2017-03-31
AU2013204727A1 (en) 2013-08-22
CA2863662A1 (en) 2013-08-08
MD20140091A2 (ro) 2015-01-31
BR112014018918A2 (https=) 2017-06-20
EP2809323A1 (en) 2014-12-10
US20150105350A1 (en) 2015-04-16
HK1202801A1 (en) 2015-10-09
WO2013116720A1 (en) 2013-08-08
WO2013116730A1 (en) 2013-08-08
KR20140119177A (ko) 2014-10-08
CN104105484A (zh) 2014-10-15
AU2016203666A1 (en) 2016-06-23
EA201491287A1 (ru) 2015-04-30
US20170056423A1 (en) 2017-03-02
AU2013204731B2 (en) 2016-03-03
JP6059255B2 (ja) 2017-01-11
BR112014018918A8 (pt) 2017-07-11
MX2014009172A (es) 2014-08-27
AU2013204731C1 (en) 2017-08-31
NZ629896A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
HK1204914A1 (en) Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
MY179392A (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
IL264402B (en) History of pyrrolo(2,3–d)pyrimidine for the treatment of viral infections and other diseases
MD4508B1 (ro) Hemifumarat de tenofovir alafenamidă şi utilizările sale medicale
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EP2709989B8 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
SMT201800064T1 (it) Derivati di pirrolopirimidina per l'uso del trattamento di infezioni virali
AU2012358805A8 (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
HK1214508A1 (zh) Tec家族激酶抑制剂辅助疗法
WO2013077921A3 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
WO2013006569A3 (en) Herpes virus vaccine and methods of use
MX2013011411A (es) Tratamiento para infeccion por el virus de hepatitis b solo o en combinacion con el virus de hepatitis delta y enfermedades hepaticas asociadas.
HK1191175A (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases